Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

What was studied

This study pooled data from past trials of JAK inhibitor pills. The pills were tested in people with alopecia areata. In this disease, the body's immune system harms its own hair roots. All people had moderate to severe disease and were aged 12 or more. Each trial compared the pills with a dummy pill, called placebo. The team searched for trials up to November 2025.

What they found

The review found 12 trials with 4141 people. Only one trial also included teens. People on the pills were more likely to regrow hair than those on placebo. This held at each time point, from week 12 to week 36. The gain looked larger at week 36 than at week 24. Side effects of any kind were more common with the pills. But serious side effects were not clearly different between the groups. Stopping the drug due to side effects was also not clearly different.

What it means for patients

The authors say these pills help hair grow back on the scalp. They also saw eyebrows and eyelashes grow back. The response seemed to rise at later time points. The authors found the safety data reassuring.

Why it is not certain yet

Some of the trials had concerns, mainly from missing data. Only one trial included teens, so data on teens is limited. The data only went up to week 36. The authors call for trials that test these drugs against each other. They also call for long-term tracking of safety. A review can only be as good as the studies in it.

Source

Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

We restate facts from the source record in our own words. The original wording belongs to its publisher.